Metformin Market Report 2026

The metformin market size has grown strongly in recent years. It will grow from $4.44 billion in 2025 to $4.73 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increasing prevalence of type 2 diabetes, adoption of oral antidiabetic drugs, affordability of generic metformin, improved healthcare access, growth of prescription monitoring programs.

The metformin market size is expected to see strong growth in the next few years. It will grow to $5.99 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to rising demand for extended-release formulations, expansion of telemedicine diabetes care, integration with wearable glucose devices, increasing focus on combination therapies, growing health awareness campaigns. Major trends in the forecast period include precision medicine-based diabetes optimization, AI-driven treatment personalization, digital glucose monitoring integration, automated pharmaceutical manufacturing, iot-enabled prescription adherence tracking.

The rising prevalence of diabetes is expected to drive the growth of the metformin market in the coming years. Diabetes is a medical condition that arises either when the pancreas produces insufficient insulin or when the body is unable to use the insulin effectively. Several factors contribute to the increasing prevalence of diabetes, including the obesity epidemic, genetic susceptibility, lifestyle changes, limited access to healthcare, and exposure to certain toxins. Metformin helps manage type 2 diabetes by reducing blood sugar levels, promoting weight loss, improving insulin sensitivity, and potentially offering additional cardiovascular benefits. For example, in February 2023, Diabetes Canada, a non-profit organization based in Canada, reported that the estimated prevalence of diabetes in Canada is expected to rise from 2,409,000 cases (15% of the population) in 2023 to 3,009,000 cases (17% of the population) by 2033. Thus, the growing prevalence of diabetes is fueling the expansion of the metformin market.

Major companies operating in the metformin market are concentrating on creating innovative diabetes treatments, such as triple-drug FDCs, to enhance their market presence. A triple-drug Fixed-Dose Combination (FDC) for diabetes medications generally refers to a single tablet or capsule that combines three distinct antidiabetic drugs. These combinations aim to provide synergistic effects in controlling blood sugar levels and improving overall glycemic management in patients with type 2 diabetes. For example, in October 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical firm, introduced the first triple-drug fixed-dose combination (FDC) of teneligliptin with dapagliflozin and metformin in India. This FDC, marketed as Zita DM, contains teneligliptin (20 mg), dapagliflozin (10 mg), and metformin SR (500 mg/1000 mg) in a fixed dose. It is intended to enhance glycemic control in adult patients with Type 2 diabetes, particularly those whose diabetes is not adequately managed by metformin alone or who need the addition of teneligliptin and dapagliflozin as separate medications.

In April 2023, SK Capital Partners LP, a US-based investment firm, completed the acquisition of Apotex Pharmaceutical Holdings Inc. for an undisclosed sum. Through this acquisition, SK Capital seeks to broaden its presence in the pharmaceutical sector by utilizing Apotex's extensive range of generic medications, including metformin. Apotex Pharmaceutical Holdings Inc. is a Canada-based pharmaceutical company that produces metformin.

Major companies operating in the metformin market are Wockhardt Limited, Aarti Drugs, Abhilash Chemicals Private Limited, Farmhispania, Rochem International Inc., Chr. Olesen Group, Aspire Lifesciences Pvt. Ltd., Ria Lifesciences Pvt. Ltd., LGM Pharma, HRV Global Life Sciences, Octavius Pharma Pvt. Ltd., USV Private Limited, Zeon Pharma Industries India Pvt. Ltd., Atman Pharmaceuticals, Anwita Drugs & Chemicals Pvt. Ltd., IOL Chemicals and Pharmaceuticals, Granules India Limited, Angels Pharma India Private Limited, Auro Laboratories Ltd, Wanbury Ltd, Shouguang Fukang Pharmaceutical Co, Vistin Pharma ASA, Keyuan Pharmaceutical.

North America was the largest region in the metformin market in 2025. The regions covered in the metformin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metformin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on imported pharmaceutical ingredients have elevated production and distribution costs for metformin, particularly affecting hospitals and pharmacies in regions relying on overseas raw materials. These tariffs can lead to temporary shortages and higher retail prices, especially in North America and Europe. However, tariffs have also encouraged growth in domestic manufacturing, stimulating competitive pricing and supply chain resilience over time.

The metformin market research report is one of a series of new reports that provides metformin market statistics, including metformin industry global market size, regional shares, competitors with a metformin market share, detailed metformin market segments, market trends and opportunities, and any further data you may need to thrive in the metformin industry. This metformin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Metformin is an oral drug mainly prescribed for the treatment of type 2 diabetes and belongs to the biguanide class of medications. It functions by lowering glucose production in the liver, enhancing insulin sensitivity to promote glucose uptake in muscle tissue, and decreasing the absorption of glucose from the intestines.

The primary forms of metformin include immediate-release tablets and extended-release tablets. Immediate-release tablets are a formulation in which the active ingredient is released rapidly after intake, allowing for quick regulation of blood glucose levels. The available dosage strengths include 500 mg, 750 mg, 850 mg, and 1 g, and these are used across various end users such as clinics, hospitals, homecare settings, and other healthcare environments.

The metformin market consists of sales of glucophage, fortamet, glumetza, riomet, and linagliptin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.